CAJ | 학술논문

目的：探讨雷珠单抗玻璃体腔内注射联合复方丹参静脉注射治疗视网膜分支静脉阻塞（BRVO ）伴发黄斑水肿的临床疗效。方法回顾性分析2014年1月至2014年5月就诊于我院眼科的视网膜分支静脉阻塞伴发黄斑水肿患者79例（79只眼），分为2组。治疗组45例（45只眼）予雷珠单抗玻璃体腔内注射联合复方丹参静脉滴注，对照组34例（34只眼）为单纯雷珠单抗玻璃体腔内注射治疗。统计分析治疗前及治疗后1周、3个月、6个月患者患眼最佳矫正视力、黄斑中心凹视网膜厚度（CMT）的改变，以及平均球内注射次数。结果治疗后1周治疗组与对照组最佳矫正视力均有提高，2组相比无明显差异（P>0.05），治疗后3个月、6个月治疗组最佳矫正视力提高均高于对照组（P＜0.05）。治疗后1周，3个月，6个月治疗组黄斑水肿程度较治疗前有所下降，二者有明显差异（P＜0.05）；治疗后1周治疗组与对照组黄斑水肿程度均有所下降，2组相比无明显差异（P>0.05），治疗后3个月、6个月治疗组黄斑水肿程度均较对照组有明显下降，二者有明显差异（P＜0.05）；治疗后1周时，治疗组与对照组治疗疗效比较无明显差异（P>0.05），治疗后3个月、6个月时治疗组疗效明显优于对照组，二者相比有明显差异（P＜0.05）。治疗至6个月时，治疗组显效患者与有效患者平均打针次数较对照组均有明显减少，二者比较有明显差异（P＜0.05）。结论采用雷珠单抗联合复方丹参治疗视网膜分支静脉阻塞伴发黄斑水肿与单纯雷珠单抗药物治疗比较，可以在更少的球内注射次数的基础上更有效地改善患者视力，减轻黄斑水肿情况，是临床上有效的治疗方式。
목적：탐토뢰주단항파리체강내주사연합복방단삼정맥주사치료시망막분지정맥조새（BRVO ）반발황반수종적림상료효。방법회고성분석2014년1월지2014년5월취진우아원안과적시망막분지정맥조새반발황반수종환자79례（79지안），분위2조。치료조45례（45지안）여뢰주단항파리체강내주사연합복방단삼정맥적주，대조조34례（34지안）위단순뢰주단항파리체강내주사치료。통계분석치료전급치료후1주、3개월、6개월환자환안최가교정시력、황반중심요시망막후도（CMT）적개변，이급평균구내주사차수。결과치료후1주치료조여대조조최가교정시력균유제고，2조상비무명현차이（P>0.05），치료후3개월、6개월치료조최가교정시력제고균고우대조조（P＜0.05）。치료후1주，3개월，6개월치료조황반수종정도교치료전유소하강，이자유명현차이（P＜0.05）；치료후1주치료조여대조조황반수종정도균유소하강，2조상비무명현차이（P>0.05），치료후3개월、6개월치료조황반수종정도균교대조조유명현하강，이자유명현차이（P＜0.05）；치료후1주시，치료조여대조조치료료효비교무명현차이（P>0.05），치료후3개월、6개월시치료조료효명현우우대조조，이자상비유명현차이（P＜0.05）。치료지6개월시，치료조현효환자여유효환자평균타침차수교대조조균유명현감소，이자비교유명현차이（P＜0.05）。결론채용뢰주단항연합복방단삼치료시망막분지정맥조새반발황반수종여단순뢰주단항약물치료비교，가이재경소적구내주사차수적기출상경유효지개선환자시력，감경황반수종정황，시림상상유효적치료방식。
OBJECTIVE To study the effect of intravitreal ranibizumab injection combined with intravenous compound salvia injection drip in the treatment of patients with macular edema secondary to branch retinal vein occlusion (BRVO). METHODS Seventy-nine patients of branch retinal vein occlusion with macular edema were analyzed retrospectively. Forty-five patients in the treatment group were treated with intravitreal ranibizumab injection combined with intravenous compound salvia injection drip, 34 patients in the control group were treated with ranibizumab injection only. All patients were recorded and analyzed changes of clinical effects after 1 week, 3 months, 6 months of treatment. BCVA and CMT were measured. RESULTS After 1 week of treatment, the two groupsˊ BCVA were significantly improved than preoperation (P<0.05), and there was no significant difference between the two group (P>0.05);after 3 months and 6 months of treatment, the treatment groupˊs BCVA improved significantly than control group (P<0.05). Both groups showed significant reduce of macular edema than preoperation (P<0.05), and there was no significant difference between the two groups (P>0.05);after 3 months and 6 months of treatment, the treatment groupˊs macular edema reduced much significantly than control group (P<0.05).The total effect between the two groups had no difference after 1 week treatment (P>0.05), but after 3months and 6 months of treatment, it showed better total effect in the treatment group than the control group (P<0.05) .After 6 months of treatment,the numbers of injections of cure and effective patients were both less in the treatment group than the control group (P<0.05). CONCLUSIONS Intravitreal ranibizumab injection combined with intravenous compound salvia injection drip could effectively improve the therapeutic effect in patients with macular edema secondary to branch retinal vein occlusion, and could effectively improve the visual activity and reduce the macular edema with less number of injections. The treatment showed great potential in the clinical use.